pharmaphorum
DECEMBER 8, 2016
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
Placebo Control
NOVEMBER 21, 2016
On this date 349 years ago, Samuel Pepys relates in his famous diary a remarkable story about an upcoming medical experiment. As far as I can tell, this is the first written description of a paid research subject. According to his account , the man (who he describes as “a little frantic”) was to be paid to undergo a blood transfusion from a sheep. It was hypothesized that the blood of this calm and docile animal would help to calm the man.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Research Ethics Blog
AUGUST 13, 2016
The Zika Virus – Image by David Goodwill (RCSB Molecule of the Month 197, June 2016). [CC BY 4.0 ( [link] )%5D, via Wikimedia Commons. A recent PBS Newshour story highlights just some of the challenges in getting a vaccine for Zika tested and out on the market. The article confirms that about 30 vaccines are being developed and tested. Currently there is a multi-centre open-label Phase 1 clinical trial underway using the GLS-5700 vaccine, developed by Inovio.
pharmaphorum
NOVEMBER 30, 2016
Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces. Key topics to be discussed include: – The challenges of launching a product in Europe – How pharma can improve its understanding of the process through the use of business intelligence – How insights from new data can be applied to the process of launch excellence – The role of real-world data in launch strategy –
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
pharmaphorum
NOVEMBER 22, 2016
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
pharmaphorum
NOVEMBER 16, 2016
Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world. This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the app
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
SEPTEMBER 8, 2016
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
pharmaphorum
AUGUST 2, 2016
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes. To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement. How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via
pharmaphorum
JULY 12, 2016
Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement.
pharmaphorum
JUNE 28, 2016
In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success. This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic p
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JUNE 27, 2016
The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year. As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year. This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it wi
pharmaphorum
APRIL 27, 2016
There are clear benefits for both Life Sciences companies and their customers in significantly improving the way they engage. Be it in terms of reputation, efficiency, profitability, or even relationship quality and longevity, engagement has and will always be the key to successful business practice. Recent exclusive research conducted in conjunction with Zephyr Health revealed that both frontline sales forces and sales management professionals want to improve engagement strategies with new tech
pharmaphorum
APRIL 26, 2016
Meeting the needs of both patients, and healthcare professionals, in today's fast changing communications landscape can be challenging, particularly against the backdrop of compliance. Putting creativity at the heart of the process can be the most effective way of tackling these challenges. Although the return on investment of creativity is not always easy to measure, the value it can bring to pharma and healthcare is increasingly evident.
pharmaphorum
FEBRUARY 23, 2016
According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources. As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous.
pharmaphorum
FEBRUARY 11, 2016
The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series. While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology.
pharmaphorum
JANUARY 27, 2016
The current market research climate in the pharmaceutical industry is one of “doing more with less”. At the same time the number of healthcare professionals engaging with market research is on the decline. So how do marketing teams cope with these two challenges and continue to produce good business intelligence for big brand decisions? Cello Health Insight’s quantitative team, IQ, argues that this is an ideal environment in which to start making greater use of advanced analytics techniques to m
pharmaphorum
NOVEMBER 2, 2016
Senior level expert panel debate on the likely impacts of a hard v soft Brexit for life sciences companies in Britain.
Placebo Control
JULY 25, 2016
It is becoming increasing accepted within the research community that patient engagement leads to a host of positive outcomes – most importantly (at least practically speaking) improved clinical trial recruitment and retention. But while we can all agree that "patient engagement is good" in a highly general sense, we don't have much consensus on what the implications of that idea might be.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
JULY 21, 2016
New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure. UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community?
pharmaphorum
JULY 5, 2016
This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric?
pharmaphorum
MAY 4, 2016
A unique Q&A session/open forum panel debate. It is likely that you interact with ‘the cloud’ on various devices, multiple times throughout the day. However, for pharma we have only just scratched the surface regarding what the cloud can offer in terms of security, connectivity and efficacy. ‘Business analytics’ and ‘cloud’ are often misunderstood. To answer this, pharmaphorum, in conjunction with industry stalwarts Equinix, present a unique Q&A event, offering the opportunity to ask any questio
pharmaphorum
JULY 14, 2016
The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world. Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the c
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
52 
Let's personalize your content